Our current therapeutic focus is on the clinical development of the novel drug, lotilaner, for the first time in human medicine. If approved, our candidate, TP-03, would be the first FDA-approved treatment for Demodex blepharitis.
We are advancing a pipeline of wholly-owned candidates that address a number of diseases with high unmet need across a range of therapeutic categories including eye care, dermatology, and infectious disease prevention.
Preservative free formulation to be tested after NDA submission
In addition to TP-03, we are developing clinical-stage product candidates focused on expanding into other areas of high unmet need including dermatology and infectious disease prevention.
Rosacea is a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging, which can flare up in response to certain triggers such as sun exposure or emotional stress. According to the U.S. National Rosacea Society, approximately 16 million people in the United States are affected by rosacea and a study estimates rosacea prevalence can represent up to 5.4% of the global population. We intend to develop TP-04 as a topical formulation.
Lyme disease is the most common vector-borne disease in the United States, caused by infection of Borrelia bacteria following bite by a tick vector. Estimates of annual cases of Lyme disease in the United States range from approximately 300,000 to 400,000. Malaria is one of the world’s highest unmet public health needs, with approximately 228 million cases and more than 400,000 deaths caused by malaria worldwide. We are developing TP-05 as an oral formulation that is designed as a prophylactic drug against Lyme disease to eradicate the tick before it can transmit the Borrelia bacteria. Further TP-05 also has the potential to cause the death of mosquitos that transmit malaria.
Please reach out to us using the form below.
Thank you for getting in touch! Someone from our team will respond shortly.